EULAR 2025 highlights… EULAR 2026 Highlights – Basic and Translational Research 22 Jul 2026 SINGLE-CELL PROFILING OF SKIN AND SYNOVIAL FIBROBLASTS IDENTIFIES OPPOSING IFN-α/β REGULATION IN PsO-ARTHRALGIA AND PsA Abstract format and assignment number: Oral presentation, OP0266 Presenting author: A. Khmelevskaia (Switzerland) Around 30%…
EULAR 2025 highlights… EULAR 2026 Highlights – Artificial Intelligence 22 Jul 2026 Beyond ‘Dr Google’: Performance of Large Language Models in Patient Counselling for Connective Tissue Diseases Abstract format and assignment number: PARE Abstract – OP013-PARE Date: Wednesday, 3 June 2026 Presenting…
EULAR 2025 highlights… EULAR 2026 Highlights – Spondyloarthritis (non-therapeutic) 22 Jul 2026 Impact of sex on clinical outcomes, treatment exposure, and spinal radiographic progression over a 10-year follow-up in axial spondyloarthritis Abstract format and assignment number: Oral presentation OP0101 Presenting author: D.…
EULAR 2025 highlights… EULAR 2026 Highlights – Spondyloarthritis (therapeutic) 22 Jul 2026 Filgotinib significantly improves disease activity in patients with active axial spondyloarthritis: primary results from the phase 3 OLINGUITO trial Abstract format and assignment number: Oral presentation OP0234 Presenting author: X.…
EULAR 2025 highlights… EULAR 2026 Highlights – Rare & Autoinflammatory Diseases 22 Jul 2026 Diagnostic yield and clinical impact of multigene autoinflammatory panels in adult routine care (2018–2025): the role of pre-test clinical suspicion Abstract format and assignment number: Poster, POS0111 Date: Thursday, 4…
EULAR 2025 highlights… EULAR 2026 Highlights – Other Connective Tissue Disease and Vasculitis 22 Jul 2026 Mosaic loss of the Y chromosome differentiates Giant Cell Arteritis from Polymyalgia Rheumatica across the GCA-PMR spectrum Abstract format and assignment number: Oral presentation, OP0120 Date: Wednesday, 3 June, 17:10-17:20…
EULAR 2025 highlights… EULAR 2026 Highlights – Metabolic & Crystal Arthropathies 22 Jul 2026 Treat-to-target continuation of urate-lowering therapy versus a urate-lowering therapy discontinuation attempt strategy in gout patients in remission (go test finale): a pragmatic open label randomised superiority trial Abstract format and…
EULAR 2025 highlights… EULAR 2026 Highlights – Rheumatoid Arthritis (therapeutic and non-therapeutic) 22 Jul 2026 CD19 CAR T-Cell Therapy in ACPA-Positive, Treatment-Refractory, Active Rheumatoid Arthritis - Data from the Phase 1 of the Prospective, Interventional COMPARE Trial Abstract format and assignment number: Oral presentation OP008 …
EULAR 2025 highlights… EULAR 2025 Highlights – SLE and APS 18 Jul 2025 Preliminary results of CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label, single-arm study Abstract format and assignment number: Oral presentation OP0074 Date: Wednesday, 11…
Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) [ACR22] Systemic Lupus Erythmatosus and Antiphospholipid Syndrome 29 Nov 20226 Dec 2022 Author: Cristiana Sieiro Santos Luong et al. (0320) described the use of metabolomic analysis of metabolites to identify biomarkers of disease activity or adverse pregnancy outcomes (APO) in SLE. Low-density…